Analysts think ABBV stock price could increase by 22%
Apr 03, 2026, 11:25 AM
0.02%
What does ABBV do
AbbVie is a North Chicago-based biopharmaceutical company that develops and sells medicines across various therapeutic areas, employing 50,000 staff since its IPO in January 2013. Key products include Humira, Botox, and NX-13 for ulcerative colitis.
32 analysts think ABBV stock price will increase by 22.12%. The current median analyst target is $255.00 compared to a current stock price of $208.81. The lowest analysts target is $189.76 and the highest analyst target is $344.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.